Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma

Inclusion Criteria:

• Diagnosis of intermediate or advanced multiple myeloma meeting criteria for at least 1 2 following:
• Intermediate- to high-M-component production rates (immunoglobulin [Ig]G > 5 g/dL or IgA > 3 g/dL or urine M component > 4 g/24 hours)
• More than one osteolytic bone lesion or radiographic evidence of diffuse osteoporosis
• β-2 microglobulin > 3
• Nonsecretory myeloma if bone marrow plasmacytosis is greater than 30%
• Must have undergone autologous peripheral blood stem cell transplantation within the past 3-4 months
• Age 18 to 69 years old
• Absolute neutrophil count ≥ 1,000/mm^3
• Platelet count ≥ 30,000/mm^3
• SGOT or SGPT ≤ 300 IU
• Bilirubin ≤ 2 mg/dL
• Creatinine ≤ 2.0 mg/dL
• Creatinine clearance ≥ 30 mL/min
• Negative pregnancy test
• Fertile patients must use effective contraception

Exclusion Criteria:

• concurrent major cardiac disease that would preclude study participation
• concurrent major pulmonary disease that would preclude study participation
• pregnant or nursing
• peripheral neuropathy ≥ grade 2
• history of hypersensitivity to bortezomib, boron, or mannitol
• concurrent major gastrointestinal or bladder disease that would preclude study participation
• concurrent major neurologic or psychiatric disease that would preclude study participation
• dementia or significantly altered mental status that would preclude giving informed consent
• prior interferon post-transplantation
• prior thalidomide post-transplantation
• prior chemotherapy post-transplantation
• prior radiotherapy post-transplantation
• prior investigational therapy post-transplantation
• prior bortezomib
• prior therapy for myeloma post-transplantation
• other concurrent anti-myeloma therapy
• other concurrent investigational therapy